Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation.

Christoph LohanAlex DiamantopoulosCorinne LeReunEmily WrightNatalie BohmLaura Marie Sawyer

Published in: BMJ open gastroenterology (2019)

Tofacitinib is an efficacious treatment for moderately to severely active ulcerative colitis and is likely to be a cost-effective use of NHS resources.

Keyphrases

ulcerative colitis
systematic review
rheumatoid arthritis
combination therapy
replacement therapy
case control
smoking cessation
network analysis